Alvotech provides update on the status of u.s. biologics license application for avt05

Reykjavik, iceland, nov. 02, 2025 (globe newswire) -- alvotech (nasdaq: alvo), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that the u.s. food and drug administration (fda) has issued a complete response letter (crl) for alvotech's biologics license application (bla) for avt05, in a prefilled syringe and autoinjector presentations, a biosimilar candidate to simponi® (golimumab).
ALVO Ratings Summary
ALVO Quant Ranking